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Abstract 
Mesenchymal stem cells (MSCs) represent an invaluable asset for the field of cell therapy. Human Bone marrow-
derived MSCs (hBM-MSCs) are one of the most commonly used cell types in clinical trials. They are currently being 
studied and tested for the treatment of a wide range of diseases and conditions. The future availability of MSCs thera-
pies to the public will require a robust and reliable delivery process. Cryopreservation represents the gold standard 
in cell storage and transportation, but its effect on BM-MSCs is still not well established. A systematic review was 
conducted to evaluate the impact of cryopreservation on BM-MSCs and to attempt to uncover the reasons behind 
some of the controversial results reported in the literature. Forty-one in vitro studies were analysed, and their results 
organised according to the cell attributes they assess. It was concluded that cryopreservation does not affect BM-
MSCs morphology, surface marker expression, differentiation or proliferation potential. However, mixed results exist 
regarding the effect on colony forming ability and the effects on viability, attachment and migration, genomic stabil-
ity and paracrine function are undefined mainly due to the huge variabilities governing the cryopreservation process 
as a whole and to the lack of standardised assays.
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Background
Bone marrow non-hematopoietic stem cells represent a 
fraction of the bone marrow cell population. They may 
arise from the constituents of the bone marrow struc-
ture and they can differentiate into mesenchymal tissues 
such as adipose, cartilage and bone. Bone marrow non-
hematopoietic stem cells were first mentioned by Julius 
Cohnheim in 1867 and later cultured and characterized 
by Freidenstein et  al. in the 1970s [1–4]. Friedenstein 
demonstrated that bone marrow non-hematopoietic 
stem can be selected by adherence to culture flask and 
exhibit the following characteristics: fibroblast morphol-
ogy, colony-forming ability and in vitro proliferation and 
differentiation potentials [5]; all of which were indicative 
of ‘stemness’ properties [6]. With that said, it must be 
noted that within the scientific community, there is still 
an ongoing discussion about the true nature of these 
cells. Two names propagated for these cells “Stromal 
Stem Cells” [7] and “Mesenchymal Stem Cells” [8, 9].
The then newly discovered source of stem cells has 
attracted great interest in medical research. In addition 
to the characteristics listed above, isolating mesenchy-
mal stem cells from bone marrow was surrounded with 
minimal ethical issues and could substitute embryonic 
stem cells [6]. Therefore, hBM-MSCs became the sub-
ject of intense research and in 1995 the first autologous 
intravenous infusion of these cells in cancer patients 
was performed [10]. Later, MSCs have been shown to 
have widespread immunomodulatory effects [11] as well 
as an angiogenic induction ability [12]. Taken together 
these characteristics enlarged the scope of application 
of hMSC-based therapies. As of April 2019, a search on 
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the U.S. National Library of Medicine (ClinicalTrials.gov) 
using the term ‘bone marrow mesenchymal stem cells’ 
retrieved 368 clinical trials aiming to treat conditions like 
stroke, graft versus host disease, osteoarthritis, crohn’s 
disease, ischemic heart disease and multiple sclerosis.
The future availability of cell therapies to the public will 
be dependent on easy and quick logistics as well as robust 
and reliable delivery process. Abazari et al. [13] suggested 
that if cell therapies “cannot be delivered clinically and 
logistically then their benefit is irrelevant”. Cryopreserva-
tion remains the cell therapy industry “standard” for bio-
preservation [14] as well as the primary option of storage 
for hMSC-based products [15]. In fact, cryostorage has 
evolved from being a marginal process in the cell therapy 
manufacturing process to become a tool widening the 
availability of stem cell therapy in particular and regen-
erative medicine in general. However, despite its evolving 
role, cryobiology is lagging behind the speed at which the 
cell therapy industry is growing.
Cryopreservation is particularly crucial for a successful 
cell therapy for various reasons. It facilitates cell trans-
port, it enables the generation of cell banks with indefi-
nite shelf-life thus ensuring off-the-shelf steady supply, 
access and availability and it gives time for quality control 
testing and in vitro assays [14, 16, 17]. In addition, cry-
ostoring therapeutic doses of cells in hospitals and clin-
ics could make cell therapy a treatment choice for many 
diseases and conditions including acute conditions [18]. 
Furthermore, cryopreserved cells are ideal for sequen-
tial treatments such as the case of chronic heart failure 
or ischemic heart disease to ensure the consistency of 
the treatment [19]. Banking cells is also an appropriate 
option from an economical and a regulatory aspect [20]. 
The logistics of administration of MSC in many immu-
notherapy trials were simply described as cryopreserv-
ing cells, thawing them when needed and administering 
them within a couple of hours. This scenario would only 
be feasible if thawed cells preserved their viability, safety 
and potency [20].
Cryopreservation of cells is associated with several 
injuries; physical and molecular. A controversy still exists 
about the efficacy of fresh cells versus cryopreserved 
and whether viability implies functionality [21]. In early 
MSC-based clinical trials, using cryopreserved cells was 
hypothesised to be the source of failure [21]. In addition, 
the variability in the outcome of MSC-based clinical tri-
als was proposed to mainly be due to the functional alter-
ations that the freeze–thaw process provokes in MSCs 
rather than the freezing method itself [17].
Human Bone marrow-derived MSCs (hBM-MSCs) 
are the most commonly used source of MSCs  in clini-
cal trials [22] and have been deployed  across 17 Euro-
pean centres manufacturing MSCs [23]. The effects of 
cryopreservation on this type of cells are not well defined. 
The aim of this review is to assess whether rigorous data 
exist regarding the impact of the freeze–thawing process 
on BM-MSCs phenotypic and functional traits. To our 
knowledge, this is the first review to factor numerous 
aspects of the freezing process (freezing solution compo-
sition, the freezing protocol, the duration of storage, the 
concentration of cells at freezing, the passage number at 
freezing as well as the thawing method) in one analysis, 
for studies conducted over about 20 years. Such detailed 
analysis may allow firm conclusions to be drawn regard-
ing BM-MSCs performance after the freeze-thawing 
process as well as help uncover possible reasons behind 
some of the controversial existing results and highlight 
areas which require further investigation.
Methods
The inclusion criteria for this review were: Articles or 
conference papers assessing the impact of cryopreserva-
tion by slow freezing on BM-MSCs in suspension. There 
was no restriction on the species from which cells were 
derived. Studies where bone marrow itself was frozen, 
where freezing of BM-MSCs was done by vitrification or 
using a 3D structure and where cryopreservation impact 
was only assessed in  vivo, were excluded. A systematic 
literature search was conducted using PubMed, Science 
direct and Google Scholar (last search performed April 
2019). Two combinations of search terms were used 
‘cryopreservation mesenchymal’ and ‘freezing mesenchy-
mal’. The output of each search was first scanned for the 
relevance of title. Articles were excluded if the topic is 
unrelated or when an eligibility criterion is not met. The 
retained articles were then screened for the relevance of 
abstracts (and in few cases materials and methods) and 
retained when meeting all the eligibility criteria (Fig. 1). 
From the 41 retained studies, information regarding the 
freezing solution composition, the freezing protocol, the 
duration of storage, the concentration of cells at freez-
ing, the passage number at freezing as well as the thawing 
method was extracted and tabulated. Next, studies were 
grouped in tables according to the “hMSC checklist” 
proposed in [24]. Cell surface marker expression, differ-
entiation potential, proliferation and growth, attachment 
and migration potential, genomic stability and paracrine 
function were examined. In addition, post-thaw viability 
and morphology information was also collated because 
they are primary evaluators of cryopreservation.
Results
Species, freezing and thawing methods
As shown in Fig. 1 41 studies met the inclusion criteria. 
MSCs were isolated from the bone marrow of 10 dif-
ferent species which included human (26 studies), rat 
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(5 studies), monkey (3 studies), dog (3 studies), horse 
(2 studies), pig (2 studies), minipig (1 study), mouse (1 
study), calf (1 study) and sheep (1 study) (Fig. 2).
Across the retained studies, various freezing media for-
mulations were used. 20% of studies (17% human) used 
commercially available freezing solution such as CELL-
BANKER and CRYOSTOR while the rest used “in-lab” 
homemade formulations. 66% of studies (41% human) 
used or tested various amounts of serum in the freezing 
media with the serum principally being animal-derived, 
20% of studies (12% human) froze cells in serum-free 
media while 5% used freezing media containing plasma or 
human platelet lysates (all of which are human studies). For 
17% of the studies, not enough information was included 
about FBS content and/or about the composition of the 
freezing medium (12% human). Of the serum-free studies, 
one study assessed the efficiency of Sericin as a substitute 
Search term: ‘Cryopreservation and Mesenchymal’ Search term: ‘Freezing and Mesenchymal’
36 retained 
by abstract 
65 
retained 
by title
695 
studies 
retrieved
Step1: PubMed Step 2: PubMed
1 retained by 
abstract
4 retained 
by title
Duplicates 
removed
518 
studies 
retrieved
Step 4: Science DirectStep 3: Science Direct
0 retained by 
abstract
13 
retained 
by title
Duplicates 
removed
1939 
studies 
retrieved
0 retained by 
abstract
4 retained 
by title
Duplicates 
removed
2222 
studies 
(research 
articles) 
retrieved
4 additional articles found via Google Scholar and through checking the references of each retained article
When screening titles and abstracts the following criteria were 
checked and studies included if:
• Topic: A cryopreservation study
• Aim: To assess cryopreservation impact
• Cell source: Bone marrow
• Research article or conference paper
When screening titles and abstracts the following criteria were 
checked and studies excluded if:
• Abstract, letter, review or article not in English 
• Freezing of bone marrow itself rather than BM-MSCs
• Freezing done by vitrification
• Freezing on a 3D structure
• Freezing impact assessed in-vivo only
Inclusion criteria Exclusion criteria
Fig. 1 Schematic representation of the Bone-marrow derived mesenchymal stem cell cryopreservation search strategy. Diagram of the current 
systematic search analysis. Studies of bone-marrow derived mesenchymal stem cells aligned to cryopreservation and/or freezing were identified 
using a combination of two search terms ‘cryopreservation mesenchymal’ and ‘freezing mesenchymal’ using PubMed, Science direct and Google 
scholar. The output of each search was scanned at the title level, then at the abstract level and articles were retained when meeting eligibility 
criteria, both inclusion and exclusion (see boxes titled inclusion criteria and exclusion criteria in this figure). In specific, for the term ‘cryopreservation 
and mesenchymal’ in PubMed, 695 studies were retrieved. By checking the titles against the eligibility criteria, only 65 studies were retained. 
The abstracts of these 65 articles were then read and checked against the eligibility criteria and only 36 of the 65 articles were retained. For the 
subsequent searches, these steps of retaining and eliminating articles were followed but preceded by eliminating duplicates i.e. articles which 
appeared in previous searches
26
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3
3
2
2
Human Rat Dog Monkey Pig Horse Mouse Calf Sheep Minipig
Fig. 2 Pie chart showing the number of studies per species. The 
numbers of studies are presented on the diagram in Arabic numerals 
unless it is only a single study i.e. where no number is presented this 
species only represents a single included study. Of note, 3 of the 41 
studies appear more than once because they have used more than 
one species, hence the total number of studies as it appears in this 
pie chart is 45
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to FBS [25]. Across all of the studies, 13 assessed the freez-
ing in xeno-free media. More than 90% of studies used 
dimethylsulfoxide (DMSO) at a concentration ranging 
from 1 to 20% with 10% being the most commonly used. 
Carboxylated poly-l-lysine (COOH-PLL) was investigated 
as a cryoprotectant to replace DMSO [26] and hydroxy-
ethyl starch was added to freezing solution as a strategy to 
reduce the percentage of DMSO [27]. Two studies tested 
various freezing solutions containing polyethylene glycol 
(PEG), trehalose and 1,2 propanediol in order to develop 
a well-defined, serum-free and reduced-DMSO freez-
ing solution [28, 29]. Only two studies utilized strategies 
to prevent post-thaw apoptosis through the addition of 
Rho-associated kinase inhibitor [30] and Caspase inhibitor 
z-VAD-fmk [31] in the freezing media.
Concerning freezing protocols, two procedures prevail. 
The first involves incubating the cells at a freezing rate 
of − 1  °C/min in a − 80  °C freezer for several hours (up 
to 24  h) then moving the cells to liquid nitrogen  (LN2). 
The second is based on a two to seven-step sequential 
freezing process using a programmable freezing device 
to freeze the cells prior to − 150 °C freezer or  LN2 stor-
age. Four studies reported whether cells were stored in 
liquid phase [32] or vapour phase [30, 33, 34] of  LN2. Five 
studies stored the cells at − 80 °C [26, 35–38] and 1 study 
stored the cells at − 70 °C [39].
Seven studies (3 human and 4 animal) did not specify 
the passage number at which cells were frozen. Six studies 
(3 human and 3 animal) used cells at passage 1, one study 
(monkey) used cells at passage 9 and the rest (20 human 
and 6 animal) used cells at passages ranging from 1 to 6. The 
concentration of cells at freezing was very variable ranging 
from 1 * 105 to 1 * 107 cells/mL with 1 * 106 cells/mL being the 
most frequently used (17 studies; 9 human and 8 animal). 
There was only one study in which human-derived cells 
were frozen in cryopreservation bags at a concentration of 
1.8 * 108 [40]. There was a huge variation regarding the dura-
tion of storage of cells in the frozen state; the shortest period 
being 1 h [30] and the longest 10 or more years [37].
Seven studies (human) did not include information 
about their thawing protocols. Two studies (1 human and 
1 animal) just mentioned ‘quickly thawed’ [20, 39], one in 
α-MEM [41], one at room temperature [37] and one in a 
37  °C incubator [42]. For all the rest (16 human and 13 
animal), there was some consistency; cells were typically 
thawed at 37 °C, most likely in a water bath with or with-
out gentle agitation for 1–4 min.
Post‑thaw assessment
Presented in Fig.  3 are how many of the forty-one 
retained studies assessed different cellular attributes, 
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Fig. 3 a Pie chart showing the proportion of the retained studies assessing different cellular attributes in all species. b Pie chart illustrating the 
proportion of human retained studies assessing different cellular attributes. It is supported by Additional file 1 which aggregates and delineates 
which studies undertook which analyses in a tabular form [arranged by species: human (chronologically and then alphabetically) and animals 
from most to least frequent species (chronologically and then alphabetically)]. Additional file 1 is a grid identifying which cell attributes each of the 
forty-one studies assessed. Of note each of the 41 studies may appear more than once depending on the attributes they assessed
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it shows that viability and differentiation potential are 
the only attributes assessed in over half of the retained 
studies.
Viability
Post-thaw viability was the most assessed  cell attribute 
(37 studies). Table 1 lists the studies which assessed via-
bility immediately post-thaw (37 studies) or after a period 
of post-thaw culture, which was monitored in five stud-
ies (post-thaw time point from 4 h to 3 passages). Three 
main methods for viability assessment were used; trypan 
blue exclusion, flow cytometry and fluorescent micros-
copy. The immediately post-thaw viability varied from 
about 50% to 100% which is noteworthy. Sixteen studies 
reported no change in viability immediately after thaw-
ing while 10 studies reported significantly lower viabil-
ity. In some studies where a new freezing formulation 
was tested, viability was compared to 10% DMSO which 
is still considered the gold standard for freezing BM-
MSCs. The timing of viability measure is crucial due to 
the induction of apoptotic events some time post-thaw 
[43]. As mentioned above only five studies assessed the 
long-term effect (up to 3 passages post-thaw of freez-
ing) with two reporting lower viability and three report-
ing no effect. It was also noted that variability in the level 
of viable cells within the same study differed when using 
different methods of measurement such as trypan blue 
exclusion compared to flow cytometry [44, 45].
Morphology
Table 2 summarises the studies which assessed post-thaw 
cell morphology. This attribute was mainly assessed using 
microscopy. Irrespective of all the variables considered 
in this data analysis and the time post-thaw at which 
cell morphology was checked, 13 of the 16 studies agree 
that cryopreservation itself has no effect on post-thaw 
cell morphology. The addition of Rho-associate kinase 
(ROCK) inhibitor Y-27632 was reported to give BM-
MSCs a web-like appearance which indicated some neu-
ronal differentiation [30]. In addition, several cell shapes 
were observed at day 2 and day 5 post-thaw [46] and cell 
shrinkage was detected using flow cytometry [38].
Immunophenotyping
Marker expression is one of the International Society for 
Cellular Therapy (ISCT) criteria for defining MSCs [47] 
so it is of real importance to check BM-MSCs pheno-
type before freezing and/or after thawing. Table  3 lists 
the studies which assessed BM-MSCs marker expression 
post-thaw. Despite its importance, less than half of the 
41 studies retained assessed post-thaw marker expres-
sion retention and despite all the variables taken into 
consideration in this investigation, there was a consensus 
regarding the methodology used (flow cytometry) and 
the results; cryopreservation does not affect BM-MSCs 
immunophenotype.
Differentiation potential
Tri-lineage differentiation (adipogenic, osteogenic and 
chondrogenic) is another criterion listed by the ISCT 
guide for defining MSCs [47]. Hence, more than half of 
the studies [24] assessed BM-MSCs post-thaw differen-
tiation potential and these are listed in Table  4. Osteo-
genesis is the most frequently assessed differentiation 
pathway (20 studies) qualitatively through Alizarin red 
staining and/or quantitatively through measurement of 
alkaline phosphatase activity. There was an agreement 
among 18 studies that cryopreservation did not affect 
BM-MSCs osteogeneic potential. One study reported 
lower osteogenesis [39] and one reported improved oste-
ogenesis post-thaw [48]. Adipogenesis was next in terms 
of frequency of testing using Oil Red O staining as a qual-
itative assessment and no effect of cryopreservation was 
observed in 12 studies. Only one study provided a quan-
titative assessment of adipogenesis and it was the only 
one reporting lower differentiation level [49].
Chondrogenesis presented as the least studied tri-linage 
differentiation pathway. Only five studies differentiated 
thawed BM-MSCs into chondrocytes with a qualitative 
assessment made via Alcian Blue staining. It was concluded 
that cryopreserved cells did not lose the ability to chondro-
genic differentiation (of note thawed BM-MSCs were also 
able to commit to neuronal and endothelial lineages).
Proliferation potential
Table  5 lists the 20 studies which examined post-thaw 
BM-MSCs proliferation potential. Various methods 
were used to determine proliferation rate such as popu-
lation doublings and DNA quantification. The major-
ity of results agree that cryopreservation does not affect 
post-thaw BM-MSCs proliferation potential, nonethe-
less lower proliferation rate was obtained by two stud-
ies [34, 39] and higher proliferation rate was obtained by 
one study [50]. Colony-forming unit ability, a traditional 
measure of BM-MSCs proliferation, was assessed by 
three studies with mixed results [25, 32, 51].
Metabolic activity
Table  6 lists the six studies which examined post-thaw 
BM-MSCS metabolic activity. Three methods were equally 
used to determine cell metabolic activity; AlamarBlue, 
Presoblue and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium) reduction-based assays. From the 
data collated it could be seen that two-thirds of experi-
ments performed reported impaired metabolic activity 
post-thaw.
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sm
en
t
 H
en
g 
[3
0]
H
um
an
Cu
ltu
re
 m
ed
iu
m
 w
ith
 1
0%
 
D
M
SO
 a
nd
 0
, 1
0 
or
 1
00
 
m
ic
ro
M
 o
f R
ho
-a
ss
oc
ia
te
 
ki
na
se
 (R
O
C
K)
 in
hi
bi
to
r 
Y-
27
63
2,
 c
oo
lin
g 
to
 
− 
80
 °C
 fo
r 2
 h
, t
he
n 
va
po
ur
 p
ha
se
 o
f L
N
2 
(1
 h
)
1.
17
 * 
10
5  c
el
ls
/m
L
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
P5
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
dr
op
pe
d 
to
 a
 ra
ng
e 
ab
ou
t 9
1.
3%
 to
 
89
.4
%
; N
o 
eff
ec
t o
f 
Y-
27
63
2 
im
m
ed
ia
te
ly
 
po
st
-t
ha
w
 b
ut
 th
er
e 
w
as
 a
n 
in
cr
ea
se
 in
 
vi
ab
ili
ty
 a
t 2
4 
h 
po
st
-
th
aw
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
 L
iu
 e
t a
l. 
[2
8]
H
um
an
13
 d
iff
er
en
t f
re
ez
in
g 
m
ed
ia
 te
st
ed
 w
ith
 
va
rio
us
 c
om
bi
na
tio
ns
 o
f 
di
ffe
re
nt
 c
on
ce
nt
ra
tio
ns
 
of
 s
er
um
, D
M
SO
, P
EG
, 
tr
eh
al
os
e 
an
d 
1.
2-
Pr
o-
pa
ne
di
ol
, e
qu
ili
br
at
io
n 
of
 c
el
ls
 w
ith
 fr
ee
zi
ng
 
m
ed
ia
 a
t 4
 °C
 fo
r 1
0 
m
in
, 
− 
80
 °C
 o
ve
rn
ig
ht
 th
en
 
LN
2 
(m
in
. 1
 w
ee
k)
1 
* 1
06
 c
el
ls
/m
L
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
, s
ha
ki
ng
 g
en
tly
 fo
r 
2 
m
in
N
/A
A
 fr
ee
zi
ng
 s
ol
ut
io
n 
co
m
po
se
d 
of
 7
.5
%
 
c(
v/
v)
 D
M
SO
, 2
.5
%
 
(w
/v
) P
EG
, 2
%
 b
ov
in
e 
se
ru
m
 a
lb
um
in
 g
av
e 
co
m
pa
ra
bl
e 
vi
ab
ili
ty
 
(a
bo
ut
 8
2.
9%
) t
o 
10
%
 D
M
SO
 (a
bo
ut
 
82
.7
%
)
Fl
ow
 c
yt
om
et
ry
–P
I
 D
oa
n 
et
 a
l. 
[9
5]
H
um
an
D
M
EM
/F
12
 w
ith
 1
0%
 
D
M
SO
, i
nc
ub
at
io
n,
 4
 °C
 
fo
r 1
0 
m
in
, −
 2
0 
°C
 fo
r 
1 
h,
 −
 8
0 
°C
 fo
r 1
 d
ay
 
th
en
 L
N
2 
(1
 y
ea
r)
1 
* 1
06
 c
el
ls
/m
L
In
 a
 w
at
er
 b
at
h 
at
 3
7 
°C
P3
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
w
as
 
re
ta
in
ed
 p
os
t-
th
aw
 
at
 7
2.
95
%
Ce
ll 
Vi
ab
ili
ty
 A
na
ly
ze
r 
(B
ec
km
an
 C
ou
nt
er
, 
U
SA
)
 F
ra
nç
oi
s 
et
 a
l. 
[4
5]
H
um
an
α-
M
EM
 w
ith
 3
0%
 F
BS
 a
nd
 
5%
 D
M
SO
, −
 8
0 
°C
 fo
r 
24
 h
 th
en
 L
N
2 
(1
 w
ee
k)
N
A
N
A
Ea
rly
 p
as
sa
ge
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
dr
op
pe
d 
to
 ≤
 6
0%
 
(A
nn
ex
in
 V
/P
I) 
an
d 
>
 8
0%
 (T
ry
pa
n 
bl
ue
); 
A
t 4
 h
 p
os
t-
th
aw
 v
ia
-
bi
lit
y 
w
as
 b
et
w
ee
n 
44
 a
nd
 6
1%
; v
ia
bi
lit
y 
in
cr
ea
se
d 
af
te
r p
os
t-
th
aw
 c
ul
tu
re
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
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Ta
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e 
1 
(c
on
ti
nu
ed
)
St
ud
y
Sp
ec
ie
s
M
et
ho
d 
of
 fr
ee
zi
ng
Co
nc
en
tr
at
io
n 
at
 fr
ee
zi
ng
M
et
ho
d 
of
 th
aw
in
g
Pa
ss
ag
e 
nu
m
be
r 
at
 fr
ee
zi
ng
Re
su
lts
 p
os
t‑
th
aw
M
et
ho
d 
of
 a
ss
es
sm
en
t
 G
in
is
 e
t a
l. 
[5
0]
H
um
an
C
ry
oS
to
r-
2,
 C
ry
oS
to
r-
5,
 
C
ry
oS
to
r-
10
 c
on
ta
in
-
in
g 
2%
, 5
%
 a
nd
 1
0%
 
D
M
SO
 re
sp
ec
tiv
el
y 
or
 
co
nv
en
tio
na
l f
re
ez
in
g 
m
ed
iu
m
 (9
0%
 g
ro
w
th
 
m
ed
iu
m
 w
ith
 1
0%
 F
C
S,
 
30
%
 b
ov
in
e 
se
ru
m
 a
lb
u-
m
in
 a
nd
 1
0%
 D
M
SO
), 
pr
e-
co
ol
in
g 
on
 ic
e 
fo
r 
10
 m
in
, s
lo
w
ly
 c
oo
le
d 
to
 
− 
5 
°C
, b
la
st
 o
f c
hi
lli
ng
 
to
 −
 2
5 
°C
, q
ui
ck
 re
tu
rn
 
to
 −
 5
 °C
, c
oo
lin
g 
to
 
− 
60
 °C
 a
t a
 ra
te
 o
f 1
 °C
/
m
in
, c
oo
lin
g 
to
 −
 1
96
 °C
 
at
 a
 ra
te
 o
f −
 2
5 
°C
 u
si
ng
 
pr
og
ra
m
m
ab
le
 c
el
l 
fre
ez
er
 th
en
 L
N
2 
(a
bo
ut
 
1 
m
on
th
 o
r 5
 m
on
th
s)
1 
* 1
06
 c
el
ls
/m
L
Th
aw
ed
 fa
st
 in
 a
 3
7 
°C
 
w
at
er
 b
at
h 
w
ith
 g
en
tle
 
ag
ita
tio
n
P2
–4
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
af
te
r 
1-
m
on
th
 fr
ee
zi
ng
 
w
as
 a
bo
ut
 9
1.
7%
 
an
d 
95
.6
%
 a
nd
 
95
.4
%
 fo
r C
ry
oS
to
r-
2,
 
C
ry
oS
to
r-
5,
 C
ry
oS
-
to
r-
10
 re
sp
ec
tiv
el
y;
 
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
af
te
r 
5-
m
on
th
 fr
ee
zi
ng
 
w
as
 a
bo
ut
 7
2%
 a
nd
 
80
%
 fo
r C
ry
oS
to
r-
5 
an
d 
C
ry
oS
to
r-
10
 
re
sp
ec
tiv
el
y
Fl
uo
re
sc
en
ce
 u
pt
ak
e:
 
ca
lc
ei
n-
A
M
, e
th
id
iu
m
 
ho
m
o-
di
m
er
-1
 M
am
id
i e
t a
l. 
[3
3]
H
um
an
90
%
 F
BS
 w
ith
 1
0%
 D
M
SO
, 
pr
og
ra
m
m
ab
le
 s
lo
w
 
fre
ez
in
g 
un
it 
th
en
 
va
po
ur
 p
ha
se
 o
f L
N
2 
(lo
ng
-t
er
m
 s
to
ra
ge
)
3 
* 1
06
 c
el
ls
/2
 m
L 
vi
al
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
, s
ha
ki
ng
 g
en
tly
 fo
r 
1–
2 
m
in
P3
 a
nd
 th
en
 c
ha
r-
ac
te
riz
ed
 a
t P
4–
6 
(w
ith
 a
no
th
er
 
fre
ez
in
g 
at
 p
as
-
sa
ge
 4
)
Vi
ab
ili
ty
 w
as
 a
bo
ut
 
80
%
 u
po
n 
th
aw
in
g 
th
en
 >
 9
5%
 a
ft
er
 
su
bs
eq
ue
nt
 p
la
tin
g 
(3
 p
as
sa
ge
s 
po
st
-
th
aw
)
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n;
 
flo
w
 c
yt
om
et
ry
—
7-
A
A
D
 M
at
su
m
ur
a 
et
 a
l. 
[2
6]
H
um
an
CO
O
H
-P
LL
s 
7.
5%
 (w
/w
) a
t 
pH
 o
f 7
.4
 O
R 
10
%
 D
M
SO
 
in
 D
M
EM
 w
ith
ou
t F
BS
, 
− 
80
 °C
 fr
ee
ze
r (
1 
w
ee
k 
or
 2
4 
m
on
th
s)
1 
* 1
06
 c
el
ls
/m
L
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
 w
ith
 g
en
tle
 s
ha
k-
in
g
P3
–5
C
ry
op
re
se
rv
at
io
n 
fo
r 
on
e 
w
ee
k 
w
ith
 P
LL
 
(0
.5
–0
.8
) d
id
 n
ot
 
aff
ec
t t
he
 v
ia
bi
lit
y 
at
 0
 h
 a
nd
 6
 h
 p
os
t-
th
aw
; C
ry
op
re
se
rv
a-
tio
n 
fo
r 2
4 
m
on
th
s 
w
ith
 P
LL
 (0
.6
5)
 
pr
ov
id
es
 p
ro
te
ct
io
n 
co
m
pa
ra
bl
e 
to
 1
0%
 
D
M
SO
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
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 p
os
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M
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 C
hi
nn
ad
ur
ai
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t a
l. 
[2
0]
H
um
an
Fr
ee
zi
ng
 m
ed
ia
, −
 8
0 
°C
 
th
en
 L
N
2 
(N
A
)
5 
* 1
06
 c
el
ls
/m
L
Q
ui
ck
ly
 th
aw
ed
 (1
–2
 m
in
)
P3
–5
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
dr
op
pe
d 
to
 a
bo
ut
 
87
%
 (t
ry
pa
n 
bl
ue
) 
an
d 
71
.5
%
 (fl
ow
 
cy
to
m
et
ry
)
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n;
 
flo
w
 c
yt
om
et
ry
—
A
nn
ex
in
 V
, P
I
 H
ol
ub
ov
a 
et
 a
l. 
[6
9]
H
um
an
60
%
 α
-M
EM
 m
ed
iu
m
 w
ith
 
30
%
 p
H
PL
 a
nd
 1
0%
 
D
M
SO
, p
ro
gr
am
m
ab
le
 
co
nt
ro
lle
d 
ra
te
 fr
ee
ze
r a
t 
ra
te
 1
 °C
/m
in
 to
 −
 8
0 
°C
 
th
en
 L
N
2 
(1
,3
,6
,7
 a
nd
 
8 
m
on
th
s)
1 
* 1
06
 c
el
ls
/m
L
N
A
P3
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
is
 
70
–9
0%
Fl
ow
 c
yt
om
et
ry
—
7-
A
A
D
 s
ta
in
in
g
 M
ol
l e
t a
l. 
[3
8]
H
um
an
4 
°C
 h
um
an
 b
lo
od
 ty
pe
 A
B 
pl
as
m
a 
co
nt
ai
ni
ng
 1
0%
 
D
M
SO
, f
ro
ze
n 
to
 −
 8
0 
°C
 
us
in
g 
ra
te
-c
on
tr
ol
le
d 
ce
ll 
fre
ez
in
g 
de
vi
ce
 (N
A
)
1–
2 
* 1
06
 c
el
ls
/m
L
N
A
P2
–4
Vi
ab
ili
ty
 re
du
ce
d 
tw
o-
fo
ld
 b
y 
cr
yo
pr
es
er
va
-
tio
n 
w
he
n 
ex
po
se
d 
to
 h
um
an
 s
er
um
 
(c
el
l c
ou
nt
 a
nd
 P
I 
in
co
rp
or
at
io
n)
Ce
ll 
co
un
te
r a
nd
 a
na
-
ly
se
r s
ys
te
m
 (C
A
SY
-
TT
); 
flo
w
 c
yt
om
et
ry
–
A
nn
ex
in
 V
, P
I
 V
er
da
no
va
 e
t a
l. 
[2
5]
H
um
an
15
 d
iff
er
en
t f
re
ez
in
g 
so
lu
tio
ns
 c
on
ta
in
in
g 
va
rio
us
 c
on
ce
nt
ra
tio
ns
 
of
 D
M
SO
 (0
, 1
, 5
, 1
0 
an
d 
10
0%
) i
n 
th
e 
pr
es
en
ce
 o
r 
ab
se
nc
e 
of
 s
er
ic
in
 a
t 1
 o
r 
5%
, c
oo
lin
g 
to
 −
 8
0 
°C
 
at
 a
 ra
te
 1
 °C
/m
in
 in
 a
 
Co
ol
Ce
ll 
co
nt
ai
ne
r t
he
n 
LN
2 
(7
2 
h)
1.
4 
* 1
05
 c
el
ls
/m
L
In
 a
 3
7 
°C
 w
at
er
 b
at
h 
as
 
qu
ic
kl
y 
as
 p
os
si
bl
e
P1
–3
H
ig
he
st
 v
ia
bi
lit
y 
(2
4 
h 
po
st
-t
ha
w
) w
as
 
ob
ta
in
ed
 u
si
ng
 
st
an
da
rd
 fr
ee
zi
ng
 
m
ed
iu
m
 (1
0%
 D
M
SO
 
an
d 
25
%
 F
BS
 in
 
cu
ltu
re
 m
ed
iu
m
); 
Vi
ab
ili
ty
 o
f c
el
ls
 (2
4 
h 
po
st
-t
ha
w
) f
ro
ze
n 
in
 
cu
ltu
re
 m
ed
iu
m
 c
on
-
ta
in
in
g 
10
%
 D
M
SO
 
an
d 
1%
 s
er
ic
in
 w
as
 
no
t s
ig
ni
fic
an
tly
 d
if-
fe
re
nt
 fr
om
 s
ta
nd
ar
d 
fre
ez
in
g 
m
ed
iu
m
Fl
uo
re
sc
en
t m
ic
ro
s-
co
py
—
D
A
PI
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 p
os
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[6
6]
H
um
an
10
%
 D
M
SO
 in
 M
es
en
cu
lt-
XF
 o
r S
TE
M
-C
EL
LB
A
N
KE
R 
at
 4
 °C
, c
ry
ov
ia
ls
 o
n 
ic
e 
th
en
 m
ov
ed
 to
 −
 8
0 
°C
 
w
ith
 a
 c
oo
lin
g 
ra
te
 
− 
1 
°C
/m
in
 fo
r 2
4 
h 
th
en
 
th
en
 L
N
2 
(N
A
)
0.
5–
1 
* 1
06
 c
el
ls
/m
L
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
 fo
r 1
 o
r 2
 m
in
P3
N
o 
di
ffe
re
nc
e 
in
 
vi
ab
ili
ty
 im
m
ed
ia
te
ly
 
po
st
-t
ha
w
 b
et
w
ee
n 
tw
o 
fre
ez
in
g 
m
ed
ia
; 
C
EL
LB
A
N
KE
R 
(8
5.
6%
) 
an
d 
10
%
 D
M
SO
 
(8
6%
); 
N
o 
si
gn
ifi
ca
nt
 
di
ffe
re
nc
e 
in
 v
ia
bi
lit
y 
be
tw
ee
n 
no
n-
cr
yo
pr
es
er
ve
d 
an
d 
cr
yo
pr
es
er
ve
d 
us
in
g 
bo
th
 m
ed
ia
Fl
uo
re
sc
en
ce
-b
as
ed
 
liv
e/
de
ad
 a
ss
ay
 im
m
e-
di
at
el
y 
po
st
-t
ha
w
; 
flo
w
 c
yt
om
et
ry
—
PI
 
(t
w
o 
pa
ss
ag
es
 p
os
t-
th
aw
)
 L
ue
tz
ke
nd
or
f e
t a
l. 
[4
0]
H
um
an
5%
 h
um
an
 a
lb
um
in
 a
nd
 
10
%
 D
M
SO
, a
ut
om
at
iz
ed
 
pr
oc
es
s 
in
 a
 p
ro
gr
am
-
m
ab
le
 fr
ee
ze
r t
he
n 
LN
2 
(2
1–
51
 d
ay
s)
1.
8 
* 1
08
 in
 c
ry
o-
pr
es
er
va
tio
n 
ba
gs
Th
aw
ed
 a
t
P3
–4
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
w
as
 
re
ta
in
ed
 a
t >
 9
0%
 
vi
ab
ili
ty
 u
si
ng
 b
ot
h 
m
et
ho
ds
 fo
r 4
 
do
no
rs
 o
ut
 o
f 5
Tr
yp
an
 b
lu
e 
ex
cl
u-
si
on
; fl
ow
 c
yt
om
et
ry
: 
7-
A
A
D
 P
ol
lo
ck
 e
t a
l. 
[6
7]
H
um
an
60
%
 p
la
sm
al
yt
e 
A
, 2
0%
 
of
 2
5%
 H
A
S 
an
d 
20
%
 
D
M
SO
 (fi
na
l c
on
ce
nt
ra
-
tio
n 
of
 D
M
SO
 w
as
 1
0%
 
by
 v
ol
um
e)
, c
on
tr
ol
le
d 
ra
te
 fr
ee
ze
r t
he
n 
LN
2 
(3
0–
45
 d
ay
s)
1–
10
 * 
10
6  c
el
ls
/m
L
Th
aw
ed
 q
ui
ck
ly
 in
 a
 3
7 
°C
P1
–6
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
w
as
 
re
ta
in
ed
 a
t >
 8
0%
 fo
r 
al
m
os
t a
ll 
sa
m
pl
es
Fl
uo
re
sc
en
t m
ic
ro
s-
co
py
—
A
cr
id
in
e 
or
an
ge
, P
I
 C
hi
nn
ad
ur
ai
 e
t a
l. 
[6
8]
H
um
an
IF
N
ɣ, 
ca
sp
as
e 
in
hi
bi
to
r 
Z-
VA
D
-F
M
K 
or
 3
-m
et
hy
l 
ad
en
in
e 
pr
e-
lic
en
si
ng
 
48
 h
 p
rio
r t
o 
cr
yo
pr
es
er
-
va
tio
n,
 5
%
 h
um
an
 s
er
um
 
al
bu
m
in
, 5
%
, 2
0%
, 4
0%
, 
90
%
 h
PL
 in
 a
M
EM
 w
ith
 
10
%
 D
M
SO
 O
R 
C
ry
oS
O
-
fre
e 
D
M
SO
-fr
ee
 c
ry
o-
pr
es
er
va
tio
n 
m
ed
iu
m
, 
co
ol
in
g 
ra
te
 1
 °C
/m
in
 
th
en
 s
te
p-
do
w
n 
fre
ez
in
g 
us
in
g 
a 
7-
st
ep
 p
ro
gr
am
 
in
 C
ry
oM
ed
 c
on
tr
ol
le
d-
ra
te
 fr
ee
ze
r t
he
n 
LN
2 
(N
A
)
5–
10
 * 
10
6  c
el
ls
/m
L
In
 a
 3
7 
°C
 w
at
er
 b
at
h 
fo
r 
1 
m
in
P2
–6
Th
e 
ad
di
tio
n 
of
 v
ar
io
us
 
co
nc
en
tr
at
io
ns
 o
f 
hu
m
an
 p
la
te
le
t 
ly
sa
te
 d
id
 n
ot
 
si
gn
ifi
ca
nt
ly
 e
nh
an
ce
 
M
SC
 re
co
ve
ry
 a
nd
 
vi
ab
ili
ty
; I
FN
ɣ p
re
-
lic
en
si
ng
 p
rio
r t
o 
cr
yo
pr
es
er
va
tio
n 
en
ha
nc
es
 th
aw
ed
 
M
SC
 s
ur
vi
va
l
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n;
 
flo
w
 c
yt
om
et
ry
—
7-
A
A
D
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at
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 p
os
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M
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 G
ra
m
lic
h 
et
 a
l. 
[1
8]
H
um
an
C
ry
oS
to
r C
S5
 m
ed
ia
, 
− 
80
 °C
 fo
r 9
0 
m
in
 th
en
 
va
po
ur
 p
ha
se
 o
f L
N
2 
(7
–3
0 
da
ys
)
1 
* 1
06
 c
el
ls
 p
er
 m
L
In
 a
 3
7 
°C
 w
at
er
 b
at
h
P3
–5
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
w
as
 
re
ta
in
ed
 a
t >
 9
5%
 
(v
ia
bi
lit
y 
on
ly
 m
ar
-
gi
na
lly
 re
du
ce
d 
af
te
r 
th
aw
in
g)
TU
N
EL
 s
ta
in
in
g;
 F
lu
o-
re
sc
en
t m
ic
ro
sc
op
y—
H
oe
ch
st
, P
I
 L
ec
ha
nt
eu
r e
t a
l. 
[3
4]
H
um
an
40
%
 P
BS
 +
 4
0%
 o
f H
SA
 
so
lu
tio
n 
(2
0%
) +
 2
0%
 
D
M
SO
 a
dd
ed
 u
nd
er
 
ag
ita
tio
n 
at
 4
 °C
, 
au
to
m
at
ed
 c
ry
of
re
ez
er
 
w
ith
 a
 9
-s
te
p 
pr
og
ra
m
 
to
 −
 1
60
 °C
 th
en
 v
ap
ou
r 
ph
as
e 
of
 L
N
2 
(N
A
)
2 
* 1
06
 c
el
ls
/m
L
Fr
ee
zi
ng
 b
ag
 is
 p
ro
te
ct
ed
 
in
 s
te
ril
e 
pl
as
tic
 b
ag
 a
nd
 
th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
 fo
r a
 fe
w
 m
in
P3
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
ra
ng
ed
 
fro
m
 a
bo
ut
 5
0%
 to
 
90
%
 w
ith
 a
bo
ut
 1
4%
 
de
cr
ea
se
 in
 v
ia
bi
lit
y
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
 Y
ua
n 
et
 a
l. 
[5
2]
H
um
an
 (B
M
-M
SC
 e
ng
i-
ne
er
ed
 to
 e
xp
re
ss
 
TR
A
IL
)
5%
 D
M
SO
, 3
0%
 F
BS
 in
 
al
ph
a-
M
EM
 O
R 
hu
m
an
 
al
bu
m
in
 w
ith
 0
.5
–2
0%
 
D
M
SO
, i
so
pr
op
an
ol
 
fre
ez
in
g 
bo
x 
ov
er
ni
gh
t 
in
, −
 8
0 
°C
 fr
ee
ze
r t
he
n 
LN
2 
(1
–3
 w
ee
ks
)
1 
* 1
06
 c
el
ls
/m
L 
or
 
5 
* 1
06
 c
el
ls
/m
L 
or
 
10
 * 
10
6  c
el
ls
/m
L
In
 a
 w
at
er
 b
at
h 
at
 3
7 
°C
 
w
ith
 g
en
tle
 s
ha
ke
 fo
r 
2 
m
in
P5
Si
gn
ifi
ca
nt
ly
 re
du
ce
d 
im
m
ed
ia
te
ly
 
po
st
-t
ha
w
 v
ia
bi
lit
y 
w
ith
 0
%
 D
M
SO
 
(5
.1
6%
); 
Im
m
ed
ia
te
ly
 
po
st
-t
ha
w
 v
ia
bi
lit
y 
in
cr
ea
se
d 
w
ith
 
in
cr
ea
se
d 
D
M
SO
%
 
in
 th
e 
fre
ez
in
g;
 1
5%
 
an
d 
20
%
 D
M
SO
 g
av
e 
re
du
ce
d 
vi
ab
ili
ty
 
(a
bo
ut
 7
0.
6%
 a
nd
 
64
.1
%
 re
sp
ec
-
tiv
el
y)
 im
m
ed
ia
te
ly
 
po
st
-t
ha
w
 s
ol
ut
io
n 
up
 to
 1
0%
; a
t 5
%
 
D
M
SO
 s
am
e 
vi
ab
ili
ty
 
ob
ta
in
ed
 fo
r d
iff
er
-
en
t c
el
l c
on
ce
nt
ra
-
tio
ns
Fl
ow
 c
yt
om
et
ry
—
A
nn
ex
in
 V
, D
A
PI
O
th
er
 s
pe
ci
es
 C
ar
va
lh
o 
et
 a
l. 
[4
4]
Ra
t
D
M
EM
 w
ith
 1
0%
 F
BS
 a
nd
 
5%
 D
M
SO
, c
el
ls
 in
cu
ba
te
 
at
 ro
om
 te
m
pe
ra
tu
re
 fo
r 
15
 m
in
 th
en
 v
ia
ls
 c
oo
le
d 
at
 3
 °C
/m
in
, 5
 °C
/m
in
, 
10
 °C
/m
in
 d
ur
in
g 
15
, 4
5,
 
10
 m
in
 re
sp
ec
tiv
el
y 
un
til
 
− 
80
 °C
 u
si
ng
 p
ro
gr
am
-
m
ab
le
 fr
ee
zi
ng
 d
ev
ic
e 
th
en
 L
N
2 
(1
 m
on
th
)
1 
* 1
07
 c
el
ls
/m
L
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
 w
ith
 c
on
st
an
t 
ge
nt
le
 s
ha
ki
ng
Fr
oz
en
 d
ow
n 
af
te
r 4
 w
ee
ks
 in
 
cu
ltu
re
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
dr
op
pe
d 
to
 a
bo
ut
 
90
.5
8%
 (t
ry
pa
n 
bl
ue
) 
an
d 
66
.2
5%
 (fl
ow
 
cy
to
m
et
ry
)
Tr
yp
an
 b
lu
e;
 fl
ow
 
cy
to
m
et
ry
—
A
nn
ex
in
 
V,
 7
-A
A
D
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 p
os
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[2
9]
Ra
t, 
m
ou
se
 a
nd
 c
al
f
14
 d
iff
er
en
t f
re
ez
in
g 
so
lu
tio
ns
 te
st
ed
 w
ith
 
va
rio
us
 c
om
bi
na
tio
ns
 o
f 
di
ffe
re
nt
 c
on
ce
nt
ra
tio
ns
 
of
 s
er
um
, D
M
SO
, P
EG
, 
tr
eh
al
os
e 
an
d 
1.
2-
Pr
o-
pa
ne
di
ol
, e
qu
ili
br
at
io
n 
fo
r 1
5 
m
in
 a
t 4
 °C
, 
− 
80
 °C
 o
ve
rn
ig
ht
 th
en
 
LN
2 
(m
in
. 1
 w
ee
k)
1 
* 1
06
 c
el
ls
/m
L
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
 w
ith
 g
en
tle
 s
ha
k-
in
g 
fo
r 2
 m
in
N
A
Th
er
e 
w
er
e 
va
ria
tio
ns
 
be
tw
ee
n 
sp
ec
ie
s 
w
ith
 re
sp
ec
t t
o 
ce
ll 
vi
ab
ili
ty
—
M
ou
se
 
M
SC
s 
w
er
e 
m
or
e 
ro
bu
st
 th
an
 ra
t 
an
d 
bo
vi
ne
 M
SC
s; 
Re
du
ce
d 
D
M
SO
 
(5
%
) w
ith
 2
%
 P
EG
, 
3%
 tr
eh
al
os
e 
an
d 
2%
 a
lb
um
in
 g
av
e 
hi
gh
er
 im
m
ed
ia
te
ly
 
po
st
-t
ha
w
 v
ia
bi
lit
y 
(9
1.
5%
 [m
ou
se
]) 
to
 
10
%
 D
M
SO
 (7
5.
3%
 
[m
ou
se
])
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
 N
aa
ld
ijk
 e
t a
l. 
[2
7]
Ra
t
C
ry
op
ro
te
ct
an
t c
on
si
st
ed
 
of
 h
yd
ro
xy
et
hy
l s
ta
rc
he
s 
of
 d
iff
er
en
t m
ea
n 
m
ol
ec
-
ul
ar
 w
ei
gh
ts
 [M
W
 =
 1
09
, 
20
9,
 3
09
, 4
09
, 5
09
, 
60
9 
kD
a]
 a
nd
/o
r D
M
SO
, 
th
en
 c
el
ls
 w
er
e 
fro
ze
n 
ac
co
rd
in
g 
to
 o
ne
 o
f 
se
ve
n 
di
ffe
re
nt
 fr
ee
zi
ng
 
pr
ot
oc
ol
s 
(N
A
)
1 
* 1
05
 c
el
ls
/0
.5
 m
L
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
P1
–3
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
w
as
 
ap
pr
ox
im
at
el
y 
85
%
; 
vi
ab
ili
ty
 a
ft
er
 3
 d
ay
s 
of
 th
aw
in
g 
w
as
 
lo
w
er
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
 D
av
ie
s 
et
 a
l. 
[4
2]
Ra
t
10
%
 D
M
SO
 in
 9
0%
 F
BS
, 
th
en
 v
ia
ls
 in
cu
ba
te
d 
fo
r 1
 h
 a
t 4
 °C
, 2
 h
 a
t 
− 
20
 °C
, o
ve
rn
ig
ht
 a
t 
− 
80
 °C
 th
en
 L
N
2 
(N
A
)
1 
* 1
06
 c
el
ls
/m
L
Th
aw
in
g 
in
 a
 3
7 
°C
 R
S 
G
al
ax
y 
S 
+ 
in
cu
ba
to
r f
or
 
ab
ou
t 5
 m
in
P1
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
w
as
 
re
ta
in
ed
 p
os
t-
th
aw
 a
t >
 9
0%
; 
Bu
t l
ow
er
 v
ia
bi
lit
y 
w
as
 o
bt
ai
ne
d 
af
te
r 
in
 v
itr
o 
ex
pa
ns
io
n 
of
 
cr
yo
pr
es
er
ve
d 
ce
lls
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
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 p
os
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[3
1]
Sh
ee
p,
 h
or
se
 a
nd
 ra
t
13
 d
iff
er
en
t f
re
ez
in
g 
m
ed
ia
 te
st
ed
 w
ith
 
va
rio
us
 c
om
bi
na
tio
ns
 
of
 d
iff
er
en
t c
on
ce
nt
ra
-
tio
ns
 o
f F
BS
, D
M
SO
, 
Tr
eh
al
os
e,
 h
yd
ro
xy
et
hy
l 
st
ar
ch
, b
ov
in
e 
se
ru
m
 
al
bu
m
in
 a
nd
 C
as
pa
se
 
in
hi
bi
to
r z
-V
A
D
-fm
k,
 
4 
°C
 fo
r 6
0 
m
in
, g
ra
du
al
 
re
du
ct
io
n 
of
 te
m
-
pe
ra
tu
re
 −
 1
 °C
/m
in
 to
 
− 
40
 °C
, −
 1
0 
°C
/m
in
 to
 
− 
70
 °C
 in
 a
 c
on
tr
ol
le
d 
ra
te
 fr
ee
ze
r t
he
n 
va
po
ur
 
ph
as
e 
of
 L
N
2 
(5
 d
ay
s)
1 
* 1
06
 c
el
ls
/m
L
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
P4
N
o 
D
M
SO
 o
r l
ow
 
D
M
SO
 g
av
e 
ve
ry
 
po
or
 v
ia
bi
lit
y;
 T
he
 
be
st
 v
ia
bi
lit
y 
w
as
 
ob
ta
in
ed
 w
he
n 
us
in
g 
FB
S 
w
ith
 1
0%
 
D
M
SO
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n 
(e
va
lu
at
ed
 a
t 0
, 2
4 
an
d 
48
 h
 p
os
t-
th
aw
)
 L
i e
t a
l. 
[9
6]
D
og
D
M
EM
 w
ith
 1
0%
 F
BS
 a
nd
 
10
%
 D
M
SO
, 4
 °C
 fo
r 1
 h
, 
− 
20
 °C
 fo
r 2
 h
, −
 8
0 
°C
 
fo
r 1
0.
5 
h 
th
en
 L
N
2 
(1
 m
on
th
)
1 
* 1
06
 c
el
ls
/m
L
Th
aw
ed
 a
t 3
7 
°C
P4
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
w
as
 
re
ta
in
ed
 p
os
t-
th
aw
 
at
 9
0.
1%
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
 Z
hu
 e
t a
l. 
[4
6]
D
og
D
M
EM
 c
on
ta
in
in
g 
10
%
 
FB
S 
an
d 
10
%
 D
M
SO
, 4
 °C
 
fo
r 1
 h
, −
 2
0 
°C
 fo
r 2
 h
, 
− 
80
 °C
 fo
r 1
0.
5 
h 
th
en
 
LN
2 
(3
 y
ea
rs
)
1 
* 1
06
 c
el
ls
/m
L
Th
aw
ed
 in
 a
t 3
7 
°C
P4
N
o 
si
gn
ifi
ca
nt
 d
iff
er
-
en
ce
 in
 c
el
l v
ia
bi
lit
y
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
 E
da
m
ur
a 
et
 a
l. 
[3
6]
D
og
C
ry
op
ro
te
ct
an
t s
ol
ut
io
n 
w
ith
 o
r w
ith
ou
t 1
0%
 
D
M
SO
 a
nd
 1
0%
 F
BS
, 
bi
of
re
ez
in
g 
ve
ss
el
 a
t 
− 
80
 °C
 in
 a
 fr
ee
ze
r 
(7
 d
ay
s)
1 
* 1
06
 c
el
ls
/m
L
Th
aw
ed
 in
 a
 3
7 
°C
 w
at
er
 
ba
th
 fo
r 1
 m
in
P1
D
M
SO
 a
nd
 F
BS
-fr
ee
 
fre
ez
in
g 
ga
ve
 h
ig
he
r 
vi
ab
ili
ty
 (a
bo
ut
 9
9%
); 
D
M
SO
 a
nd
 F
BS
 
co
nt
ai
ni
ng
 fr
ee
zi
ng
 
m
ed
ia
 g
av
e 
lo
w
er
 
vi
ab
ili
ty
 (a
bo
ut
 
89
.7
%
)
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
 N
its
ch
 e
t a
l. 
[9
7]
M
on
ke
y
Fr
ee
zi
ng
 m
ed
iu
m
 c
on
ta
in
-
in
g 
0,
1,
5,
10
 o
r 1
5%
 
D
M
SO
 (v
/v
), 
co
nt
ro
lle
d 
ra
te
 fr
ee
ze
r u
si
ng
 a
n 
op
tim
is
ed
 fr
ee
zi
ng
 ra
te
 
th
en
 −
 1
50
 °C
 fr
ee
ze
r 
(1
 w
ee
k)
1 
* 1
06
 c
el
ls
/m
L
In
 a
 3
7 
°C
 w
at
er
 b
at
h
P9
Im
m
ed
ia
te
ly
 p
os
t-
th
aw
 v
ia
bi
lit
y 
w
as
 
ab
ou
t 8
0%
 fo
r t
he
 
di
ffe
re
nt
 D
M
SO
 
co
nc
en
tr
at
io
ns
; 
H
ig
he
st
 v
ia
bi
lit
y 
24
 h
 
po
st
-t
ha
w
 fo
r c
el
ls
 
fro
ze
n 
w
ith
 5
 o
r 1
0%
 
D
M
SO
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
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 p
os
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l. 
[4
9]
M
on
ke
y
Th
re
e 
di
ffe
re
nt
 fr
ee
zi
ng
 
so
lu
tio
ns
 te
st
ed
 (2
 o
f 
th
em
 x
en
o-
fre
e)
 c
on
-
ta
in
in
g 
di
ffe
re
nt
 c
on
ce
n-
tr
at
io
ns
 o
f D
M
EM
, D
M
SO
 
an
d/
or
 F
BS
, m
et
hy
lc
el
-
lu
lo
se
, p
ol
ox
am
er
-1
88
, 
α-
to
co
ph
er
ol
, c
el
l 
su
sp
en
si
on
 e
qu
ili
br
at
ed
 
fo
r 1
0,
 3
0 
or
 6
0 
m
in
 th
en
 
pl
ac
ed
 in
 c
on
tr
ol
le
d 
ra
te
 fr
ee
ze
r u
si
ng
 o
ne
-
st
ep
 fr
ee
zi
ng
 p
ro
to
co
l 
or
 tw
o-
st
ep
 fr
ee
zi
ng
 
pr
ot
oc
ol
 th
en
 −
 1
50
 °C
 
(a
t l
ea
st
 2
4 
h)
1 
* 1
06
 c
el
ls
/m
L
In
 a
 3
7 
°C
 w
at
er
 b
at
h 
fo
r 
90
 s
N
A
Vi
ab
ili
ty
 m
ai
nt
ai
ne
d 
af
te
r t
ha
w
in
g
A
ut
om
at
ic
 c
el
l c
ou
nt
er
 O
ck
 a
nd
 R
ho
 [5
1]
Pi
g
A
D
M
EM
 s
ol
ut
io
n 
su
p-
pl
em
en
te
d 
w
ith
 1
0%
 
FB
S 
an
d 
1%
 p
en
ic
il-
lin
–s
tr
ep
to
m
yc
in
 w
ith
 
40
%
, 2
0%
 o
r 1
0%
 D
M
SO
, 
co
nt
ro
lle
d 
ra
te
 p
ro
gr
am
-
m
ab
le
 fr
ee
zi
ng
 d
ev
ic
e 
at
 
− 
1 
°C
/m
in
 fr
om
 2
5 
°C
 to
 
− 
80
 °C
 th
en
 th
en
 L
N
2 
(<
 1
 m
on
th
)
2 
* 1
06
 c
el
ls
/m
L
In
 a
 3
7 
°C
 w
at
er
 b
at
h 
fo
r 
1 
m
in
P5
Th
er
e 
w
as
 a
 s
ig
ni
fic
an
t 
di
ffe
re
nc
e 
be
tw
ee
n 
fre
sh
 a
nd
 c
el
ls
 
cr
yo
pr
es
er
ve
d 
w
ith
 
10
%
 (a
bo
ut
 7
7.
6%
) 
or
 2
0%
 D
M
SO
 (a
bo
ut
 
67
%
); 
N
o 
si
gn
ifi
ca
nt
 
di
ffe
re
nc
e 
be
tw
ee
n 
fre
sh
 a
nd
 c
el
ls
 
cr
yo
pr
es
er
ve
d 
w
ith
 
5%
 D
M
SO
 (a
bo
ut
 
83
.9
%
)
Tr
yp
an
 b
lu
e 
ex
cl
us
io
n
 R
om
an
ek
 e
t a
l. 
[9
8]
Pi
g 
(B
M
-M
SC
 tr
ea
te
d 
w
ith
 a
 h
ig
h 
hy
dr
o-
st
at
ic
 p
re
ss
ur
e 
(H
H
P)
 
be
fo
re
 fr
ee
zi
ng
)
10
%
 D
M
SO
, 2
 h
 a
t 
− 
20
 °C
 th
en
 L
N
2 
(u
p 
to
 
4 
w
ee
ks
)
N
A
37
 °C
 w
at
er
 b
at
h 
w
ith
 
ge
nt
le
 s
ha
ki
ng
N
A
Si
gn
ifi
ca
nt
 d
iff
er
-
en
ce
 b
et
w
ee
n 
ce
lls
 
tr
ea
te
d 
w
ith
 H
H
P 
an
d 
co
nt
ro
l i
m
m
e-
di
at
el
y 
po
st
-t
ha
w
 
(a
bo
ut
 7
5.
2%
–
81
.7
%
); 
N
o 
di
ffe
re
nc
e 
in
 v
ia
bi
lit
y 
at
 8
 d
ay
s 
po
st
-t
ha
w
 (a
bo
ut
 
81
.6
%
–8
2.
1%
)
Tr
yp
an
 b
lu
e 
ex
cl
us
io
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Apoptosis and senescence levels
Typically assessed using flow cytometry, the induction 
of apoptosis is evident when considering the six studies 
entered in Table  7. However, cryopreservation does not 
seem to induce senescence (refer Table 7) although more 
studies are needed to draw a firm conclusion.
Attachment and migration
Only four studies assessed BM-MSCs attachment ability 
post-thaw, and these are recorded in Table 8. This table 
indicates that frozen cells have lower adherence capa-
bility post-thaw. Only one study assessed post-thaw cell 
migration [52]. It concluded that cryopreservation has no 
effect on post-thaw cell migration ability.
Paracrine function
Paracrine function is related to two main MSCs activities 
namely immunomodulation and angiogenesis. In total, 
10 studies (Refer Table 9) assessed BM-MSCs paracrine 
function with immunomodulation being the most fre-
quently assessed with eight studies. The results of these 
studies are equally balanced with four of them reporting 
no effect of cryopreservation on BM-MSCs post-thaw 
immunomodulatory potential and four reporting an 
impaired potential. Angiogenesis potential and secretion 
of growth factors were only assessed by one study each 
with no effect of cryopreservation reported.
Discussion
A recent analysis of MSC-based clinical trials showed 
that although no safety concerns surround MSC infusion, 
the translation from bench to bedside is still confronted 
by what the authors called the ‘Achilles heel’; donor 
heterogeneity, ex  vivo expansion, immunogenicity and 
cryopreservation [53]. There is no doubt that cryopreser-
vation is essential for MSC therapy translation, both 
autologous and allogeneic, and is still one the limitations 
to be addressed.
Cryopreservation by slow freezing can cause two types 
of cell damage; physical and molecular. Physical injuries 
were the first to be identified and include ice nucleation, 
solution effects, osmotic shock, cold shock as well as cry-
oprotectant toxicity [14]. Molecular injuries encompass 
the effect of cryopreservation on gene expression, protein 
levels, cell functionality, the induction of stress response 
as well as post-thaw epigenetic changes [54, 55].
Table 2 Bone-marrow derived mesenchymal stem cell studies assessing post-thaw cell morphology
The key results on bone-marrow derived mesenchymal stem cell morphology are presented in this table. For further details on the cryopreservation experimental 
details refer to either Table 1 or Additional file 2 which provide the individual freezing protocols outlined in the extracted papers alongside the concentration and 
passage of cells at the point of cryopreservation and the process of thawing
Study Species Results post‑thaw Method of assessment
Human
 Kotobuki et al. [92] Human No effect on morphology Microscopy (fluorescent/phase contrast)
 Haack-Sorensen et al. [19] Human No effect on morphology NA
 Xiang et al. [93] Human No effect on morphology Microscopy (light) at cell confluency post-thaw
 Zhao et al. [94] BM-MSC (human with 
chronic myeloid 
leukemia)
No effect on morphology NA
 Heng [30] Human The addition of Y-27632 altered the morphol-
ogy of the cells (web-like appearance)
NA
 Liu et al. [28] Human No effect on morphology Microscopy (fluorescent)
 Doan et al. [95] Human No effect on morphology Microscopy (light) 7 days post
 Mamidi et al. [33] Human No effect on morphology NA
 Moll et al. [38] Human Effect of cryopreservation seen on forward 
scatter but not side scatter when exposed to 
human serum
Microscopy; cell counter and analyser system 
(CASY-TT); Flow cytometry
 Al-Saqi et al. [66] Human No effect on morphology Microscopy (light) two passages post
Other species
 Liu et al. [29] Rat, mouse and calf No effect on morphology Microscopy (light)
 Naaldijk et al. [27] Rat No effect on morphology Microscopy (light)
 Davies et al. [42] Rat No effect on morphology Microscopy (phase contrast)
 Zhu et al. [46] Dog Cells had several shapes such as long fusiform, 
polygon and astroid
Checked at days 2 and 5 after thawing NA
 Edamura et al. [36] Dog No effect on morphology Microscopy (light)
 Mitchell et al. [32] Horse No effect on morphology Microscopy (light) (24 and 72 h post)
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In the case of MSCs, studying the effect of molecular 
injuries and how to mitigate them is a twofold problem. 
Firstly, investigating molecular injuries is still a develop-
ing branch of cryobiology. In fact, immediately post-thaw 
cell viability has always been the most assessed cell attrib-
ute in cryopreservation studies. However, it has been 
shown that signs of cellular damage may take some time 
to manifest (cryopreservation-induced delayed-onset 
cell death [54]). Leading to viability and functional losses 
which are compounded by a lack of detection and report-
ing in immediate post-thaw analysis. Approaches to 
tackle molecular injuries, intracellular-like freezing solu-
tions and anti-apoptotic compounds, can be deployed yet 
research in this area is still at an early stage [54].
Secondly, establishing and standardising potency 
markers and assays to characterise MSCs is still a chal-
lenge [24]. In fact, MSCs possess variability in their 
gene expression profiles, differentiation and expansion 
potential and phenotype depending on tissue origin, 
cell isolation and expansion procedures [56] as well as 
donor characteristics [57]. In 2006, the ISCT published 
a guideline on minimal criteria to define MSC; plas-
tic adherence, expression of certain surface markers 
and lack of others and tri-lineage differentiation [47]. In 
2013, these criteria were expanded to include a fourth 
parameter, quantification of MSC immune functional 
potency [58]. In 2016, the society suggested “a matrix 
assay approach: quantitative RNA analysis of selected 
gene products; flow cytometry analysis of functionally 
relevant surface markers and protein-based assay of the 
secretome” in order to fulfil the fourth criterion [59].
Currently, there are no standard markers or potency 
assays to typify MSCs or evaluate their post-thaw potency 
despite much discussion within the scientific commu-
nity [24, 60]. Therefore, research laboratories follow dif-
fering protocols which makes data evaluation complex. 
As both research areas (freezing molecular injuries and 
MSC characterisation) develop so will the methodology 
of evaluating MSC cryopreservation.
There are profound variabilities in the whole cryo-
preservation process from freezing media formulation, 
method of freezing and thawing and duration of storage 
Table 3 Bone-marrow derived Mesenchymal Stem Cell studies evaluating surface marker expression post-thaw
The main results on bone-marrow derived mesenchymal stem cell surface marker expression are presented in this table. For further details on the cryopreservation 
experimental details refer to either Table 1 or Additional file 2 which provide the individual freezing protocols outlined in the extracted papers alongside the 
concentration and passage of cells at the point of cryopreservation and the process of thawing
Study Species Results post‑thaw Method of assessment
Human
 Kotobuki et al. [92] Human No difference Flow cytometry
 Haack-Sorensen et al. [19] Human No difference Flow cytometry
 Xiang et al. [93] Human No difference Fluorescent sorting at passage 1, 5, 10 and 15 
post-thaw
 Zhao et al. [94] Human (with 
chronic 
myeloid 
leukaemia)
No difference Flow cytometry
 Doan et al. [95] Human No difference Flow cytometry
 Ginis et al. [50] Human No difference except lower expression of CD9 Flow cytometry
 Mamidi et al. [33] Human No difference Flow cytometry
 Matsumura et al. [26] Human No difference Flow cytometry
 Holubova et al. [69] Human No difference Flow cytometry
 Moll et al. [38] Human No difference Flow cytometry
 Al-Saqi et al. [66] Human No difference Flow cytometry
 Luetzkendorf et al. [40] Human No difference Flow cytometry
 Yuan et al. [52] Human 
(BM-MSC 
engineered to 
express TRAIL)
No difference Flow cytometry
Other species
 Naaldijk et al. [27] Rat No difference Flow cytometry
 Davies et al. [42] Rat No change in the expression of CD29 and CD73; 
Increase in the expression of CD90, CD44 and 
CD105
Flow cytometry for CD29 and CD90; RT-qPCR for 
CD44, CD105 and CD73
 Ock and Rho [51] Pig No difference Flow cytometry
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to passage number and cell concentration at freezing. 
However, despite all these variabilities and all the spe-
cies included, there was evidence showing that four BM-
MSCs attributes are stable and unaffected by the stresses 
imposed by freezing and thawing and these are: cell mor-
phology, marker expression, proliferation potential and 
tri-lineage differentiation capability (although chondro-
genesis was only assessed by five independent studies). 
The four other attributes viability, attachment and migra-
tion, genomic stability and paracrine function were gov-
erned by either conflicting results or by low assessment 
frequency.
All studies have employed a strategy to evade freezing 
and thawing physical damage. Freezing BM-MSCs at a 
slow cooling rate (at least at the start of the cooling pro-
cess) and thawing at a high rate was followed by almost 
all the studies in this review. In terms of media formu-
lation, DMSO remains the most commonly used cryo-
protectant to protect BM-MSCs (used by 90% of studies 
analysed). However, DMSO is associated with adverse 
effects such as cardiac side effects [61, 62] and severe 
neurotoxicity [63, 64] when infused in patients. Conse-
quently, reducing or eliminating DMSO, depending on 
clinical outcome, may become a requisite.
Mixing other potential cryoprotectants with DMSO at 
percentages < 10% indicates that this traditionally held 
protectant and percentage can both be altered [26–28]. 
This is an interesting result which indicates that eliminat-
ing DMSO from freezing solution is a viable option and 
is worthy of further evaluation based on a wider post-
thaw MSC functional characteristics. Another impor-
tant aspect of MSC cryopreservation is the fact that FBS 
is commonly added to freezing solutions for its benefits 
to stabilise the cell membrane and adjust cell osmotic 
pressure [65]. The main issue in using FBS is that it is 
animal-derived and may cause a xenogenic reaction if 
infused in patients [65]. Cryopreserving hBM-MSCs in 
xeno-free media was assessed across 13 studies [18, 26, 
34, 38, 40, 48–50, 52, 66–69]. Verdanova et al. reported 
using Sericin (a protein derived from silkworm cocoon) 
as an FBS substitute  for preserving human BM-MSCs 
[25]. The possibility of overlapping xeno-free and low or 
no DMSO exists in one study where monkey BM-MSCs 
were successfully frozen in xeno-free solution composed 
of methylcellulose, poloxamer, α-tocopherol and only 
2.5% DMSO [49]. Such a freezing solution would be ideal 
because it is not only xeno-free but also contains a very 
low DMSO concentration.
Cell concentration at freezing and the duration of stor-
age are not well studied, and it is not well documented 
if it plays a role in the performance of the end-product. 
The only study which tested cell viability after freezing at 
three different cell concentrations found no significant 
variation [52]. In regard to duration of storage, of note 
is the study where BM-MSCs were stored for more than 
10  years without losing multipotency [37]. This could 
well be a suggestion that once cells enter a quiescent 
state, its duration is not of great significance.
Table 6 Bone-marrow derived mesenchymal stem cell studies evaluating post-thaw metabolic activity
The key results on bone-marrow derived mesenchymal stem cell metabolic activity after cryopreservation are presented in this table. For further details on the 
cryopreservation experimental details refer to either Table 1 or Additional file 2 which provide the individual freezing protocols outlined in the extracted papers 
alongside the concentration and passage of cells at the point of cryopreservation and the process of thawing
Study Species Results post‑thaw Method of assessment
Human
 Liu et al. [28] Human Reduced-DMSO freezing solution gives comparable meta-
bolic activity to 10% DMSO
AlamarBlue assay
 Chinnadurai et al. [20] Human No reduction in metabolic fitness Calcium uptake; PrestoBlue reduction
 Chinnadurai et al. [68] Human The addition of various concentrations of hPL (human 
platelet lysate) did not significantly enhance MSC meta-
bolic activity
PrestoBlue reduction
Other species
 Liu et al. [29] Rat, mouse and calf In general, non-cryopreserved cells showed higher overall 
metabolic activities than the cryopreserved; Reduced 
DMSO (5%) with 2% PEG, 3% trehalose and 2% albumin 
give superior results to 10% DMSO
AlamarBlue assay
 Nitsch et al. [97] Monkey Lower metabolic activity for cryopreserved cells com-
pared with fresh; Enhnaced levels of metabolic activity 
obtained for 5% and 10% DSMO levels
MTT assay (24 h, 48, 72 and 96 h post-thaw)
 Lauterboeck et al. [49] Monkey Cells’ metabolic activity was impaired up until 48 h post-
thaw; Partial recovery at 72 h and full recovery observed 
at 96 h
MTT assay (24 h, 48, 72 and 96 h post-thaw)
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The evaluation of the cryopreservation process is cer-
tainly an existing challenge. Our understanding of the 
biology of MSCs is evolving and so are the possibilities 
of the application of these cells in the medical field. Yet, 
as stated recently  “Significant challenge remains the 
development of a  relevant potency assay” [34]. These 
assays must be quick, easy and should  not require 
trained personnel if they are to be used to release each 
cell batch in a clinical setting and if they are to fit with 
operation theatre logistics (thawing, testing and infus-
ing within a couple of hours). In theory, potency assays 
could be therapy-specific and must indicate cell func-
tionality; in other words, “mechanism(s) of action” 
[70]. How much these assays correlate with the in vivo 
niche is also of great importance. In addition, “the assay 
should be able to differentiate between sufficiently 
potent and sub-potent batches, a (semi-)quantitative 
assay is required” [56]. This thawing-infusing scenario 
would be realistic only if cryopreservation methods 
have improved to give an optimal product immediately 
after thawing.
Cell morphology (shape and size) can give indication 
on cell’s health as well as whether they have committed to 
differentiate or not. The absence of change in BM-MSCs 
morphology after cryopreservation can indicate that the 
freeze-thaw process does not cause differentiation or 
Table 7 The induction of apoptosis in post-thaw BM-MSCs
The key results on bone-marrow derived mesenchymal stem cell apoptotic activity post-thaw are presented in this table. For further details on the cryopreservation 
experimental details refer to either Table 1 or Additional file 2 which provide the individual freezing protocols outlined in the extracted papers alongside the 
concentration and passage of cells at the point of cryopreservation and the process of thawing
Study Species Results post‑thaw Method of assessment
Apoptosis
 Human
  Liu et al. [28] Human Serum-free reduced-DMSO freezing solution 
gives comparable apoptotic percentage to 
10% DMSO
Flow cytometry
  Ginis et al. [50] Human Lower percentage of apoptotic cells obtained 
with Annexin V and Hoechst staining com-
pared to caspase 3 assay: using caspase 3, the 
percentage of apoptotic cells was between 
13 and 17% for CryStor media compared to 
3% for conventional freezing media
Flow cytometry—Annexin V, Hoechst, Caspase 
3 activity
  Chinnadurai et al. [20] Human Higher percentage of apoptotic cells in cryo-
preserved MSC than live MSC
Flow cytometry
  Moll et al. [38] Human Apoptosis increased by cryopreservation when 
exposed to human serum
Flow cytometry—Annexin V, PI staining
 Other species
  Ock and Rho [51] Pig Bak and Bcl2 gene expression in cryopreserved 
cells was higher than fresh at 3 h post-thaw: 
Bak and Bcl2 gene expression in cryopre-
served cells was comparable to fresh after 
culturing thawed cells up to 90% confluence: 
Bcl2 antigen expression level was compara-
ble to fresh after culturing thawed cells up to 
90% confluence
RT-qPCR for Bak and Bcl2: Flow cytometry; Bcl2 
antigen
  Romanek et al. [98] Pig (BM-MSC treated 
with HHP before 
freezing)
No significant difference between control 
(without HHP) and cells subjected to HHP 
pre-freeze
Flow cytometry—Annexin V: Fluorescence 
microscopy
Senescence
 Human
  Mamidi et al. [33] Human No difference in the level of senescent cells Β-galactosidase assay
  Al-Saqi et al. [66] Human There were signs of senescence (but could 
be due to culture medium rather than cryo-
preservation medium)
Β-galactosidase assay (analysed 2 passages after 
cryopreservation)
  Pollock et al. [67] Human Immediate pre-freeze senescence levels show 
similar trends but higher levels compared to 
pre-freeze At 48 h post-thaw, level of senes-
cent cells dropped significantly comparing to 
immediately post-thaw
Beta-glo assay
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change in cell phenotype. This conclusion is further evi-
denced by the absence of effect of cryopreservation on 
BM-MSCs marker expression post-thaw.
No such firm conclusion can be drawn when it comes 
to viability. This is of real importance given that viabil-
ity is one of the release criteria for cell therapies. In 
fact, viability has and will always be the primary indica-
tor on cryopreservation success. It is an easy, cheap and 
fast measurement but is has some limitations. The vari-
ous methods used across labs to measure viability and 
the lack of a unified reporting structure makes it hard 
to compare results. Although ≥ 90% viability for fresh 
MSC product and ≥ 70% viability for cryopreserved 
MSC product are generally considered the benchmark 
for clinical application [57], different labs report viabil-
ity maintenance or loss of viability based on comparison 
with pre-freeze viability or on comparison with freezing 
with 10% DMSO (refer Table 1). In addition, the common 
measurement time-point, only immediately post-thaw 
could be misleading due to the late manifestation of the 
effect of current cryopreservation protocols on cells.
In fact, the initiation of apoptotic events is evident 
according to the data in Table 7. Despite the importance 
of this cryopreservation-related cell death, it is surpris-
ing how limited the investigation of this molecular path-
way in thawed BM-MSCs is and the strategies to reduce 
it are. Only two studies utilized strategies to prevent 
post-thaw apoptosis (molecular injury). The addition of 
Rho-associated kinase inhibitor Y-27632 in the freezing 
medium and in the post-thaw culture medium did not 
improve hBM-MSCs viability immediately but recorded 
enhanced recoveries at 24-h post-thaw [30]. However, the 
addition of Caspase inhibitor z-VAD-fmk in the freezing 
media did not prove to be beneficial for equine, ovine and 
rodent BM-MSCs as assessed by viability immediately, at 
24 and 48 h post-thaw [31].
An expert workshop on preservation and stability of 
cell therapy products was held in May 2015 [71]. Assess-
ing post-thaw viability was one of the topics discussed 
and the limitations/conflicts mentioned above were 
identified. The group advised that assessing cell viability 
post-thaw should “go beyond simple enumeration of cell 
numbers to facilitate a greater understanding of the cell 
system in question”. In addition, the group realised the 
need for more advanced and accurate methods to assess 
cell viability that can be linked to cell function [71].
Interestingly, impaired cell metabolism can be closely 
associated with apoptotic pathways through the Bcl-2 
family proteins which initiates apoptosis in metabolically 
stressed cells through utilization of autophagy as a nutri-
ent source before ultimately undergoing necrosis [72, 73]. 
From the data presented in Table  6 some impairment 
of BM-MSCs metabolic activity post-thaw is evident. 
Therefore, a link between defective metabolic activity in 
thawed BM-MSCs and a higher level of apoptosis post-
thaw could be postulated. This may indicate new path-
ways to mitigate against these post-thaw phenomena.
Table 8 Bone-marrow derived Mesenchymal Stem Cell studies evaluating cellular attachment post-thaw
The effects of cryopreservation on bone-marrow derived mesenchymal stem cell attachment are presented in this table. For further details on the cryopreservation 
experimental details refer to either Table 1 or Additional file 2 which provide the individual freezing protocols outlined in the extracted papers alongside the 
concentration and passage of cells at the point of cryopreservation and the process of thawing
Study Species Results post‑thaw Method of assessment
Attachment
 Human
  Heng [30] Human Level of adherent cells was 39.8 ± 0.9%; 
increased by approx. 10% with Y-27632
MTT assay performed 24 h post-thawing
  Chinnadurai et al. [20] Human 40% reduction in adhesion to fibronectin; 80% 
reduction in adhesion to endothelial cells; No 
reduction in the surface expression of adhe-
sion molecules
After 2 h in static and 1 h in vascular flow condi-
tions using microscopy (light); Flow cytometry 
for adhesion molecules
 Other species
  Li et al. [96] Dog Decreased adhesion capacity post-thaw; 
recovery of adhesion capacity after culturing 
for several passages
Adherent cell count (hemo-cytometer) at 4, 8, 12 
and 24 h post-thaw
  Tokumoto et al. [48] Monkey Limited influence of cryopreservation on cell 
adhesion capabilities
Adherent cell count (hemo-cytometer)
Migration
 Human
  Yuan et al. [52] Human (BM-MSC engi-
neered to express 
TRAIL)
No effect on migration potential Trans-well plates
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More research is needed if cells are to be thawed and 
immediately infused in patients. Infusing apoptotic 
cells will hinder MSCs therapeutic benefits. Moreo-
ver, it is vital that therapeutic cells emerge potent from 
freezing to be capable to survive in a damaged tissue 
where they will encounter a hostile environment with 
mechanical, hypoxia and nutritional stresses, the host 
immune response and inflammation. These factors are 
known to cause a huge loss in MSC viability after trans-
plantation as well as poor engraftment [74]. According 
to Table  8, frozen cells have lower adherence capabil-
ity. One study has tried to examine this post-thaw phe-
nomena in more detail lending evidence to a disruption 
of F-actin polymerization rather than shedding of sur-
face adhesion receptors [20]. Advancing our knowledge 
in this area will help manufacture clinical MSCs with 
improved regenerative engraftment, although the con-
cept of MSCs proliferating, differentiating and engraft-
ing in host tissue as their primary therapeutic modality 
has been recently challenged [75].
Generally, it can be said that cryopreservation does 
not affect BM-MSCs proliferative capacity (Table  5). 
However, intriguing evidence is presented by Ginis 
et al. [50] on the potential cell selection that the cryo-
preservation process may enforce. In this study, BM-
MSCs post-thaw proliferation potential was higher than 
that at pre-freeze. The authors justified their results as 
“selection of stronger cells after cryopreservation” and 
suggested that their results should “alarm a scientific 
community”. This same theory has also been mentioned 
Table 9 Published experimental studies detailing BM-MSCs post-thaw paracrine function
Summary of the effects of cryopreservation on bone-marrow derived mesenchymal stem cell paracrine function are presented in this table. For further details on 
the cryopreservation experimental details refer to either Table 1 or Additional file 2 which provide the individual freezing protocols outlined in the extracted papers 
alongside the concentration and passage of cells at the point of cryopreservation and the process of thawing
Study Species Results post‑thaw Method of assessment
Immunomodulatory potential
 Human
  Zhao et al. [94] Human (with chronic 
myeloid leukae-
mia)
No effect on immunomodulatory potential Mixed leukocyte reaction inc. T-cell proliferation
  François et al. [45] Human Impaired inhibition of proliferation of activated 
T cells; low IDO protein expression in 
response to INF-γ stimulation; up-regulation 
of heat shock proteins
T-cell proliferation assay (CD3/CD28); Western 
blot IDO; RT-qPCR IDO, CCL2, IL-6
  Holubova et al. [69] Human No effect on immunomodulatory potential T-cell proliferation (PHA)
  Moll et al. [38] Human Impaired immunomodulatory properties RT-qPCR IDO, IL-6; Western blot IDO; Instant 
blood mediated inflammatory reaction 
(IBMIR)
  Luetzkendorf et al. [40] Human No effect on immunomodulatory potential Co-culture with PBMC; T-cell proliferation (PHA)
  Chinnadurai et al. [68] Human Freeze-thawing attenuates immunosuppres-
sive properties of human MSC independent 
of freezing methods or freezing media; 
Thawed MSC can suppress T-cell prolif-
eration in the absence of cell contact; IFNɣ 
pre-licensing prior to cryopreservation 
enhances thawed MSC’s immunosuppressive 
properties
Co-culture with PBMC; T-cell proliferation (CD3/
CD28 & SEB); RT-qPCR IDO, Hsp
  Gramlich et al. [18] Human No effect on immunomodulatory potential Co-culture with PBMC; T-cell proliferation (CD3/
CD28); IDO activity assay (kynurenine)
  Lechanteur et al. [34] Human Impaired immunomodulatory properties Co-culture with PBMC; T-cell proliferation (CD3/
CD28); IDO activity assay (kynurenine)
Angiogenesis potential
 Human
  Haack-Sorensen et al. [19] Human No effect on the capacity of MSC to differenti-
ate into endothelial cells; Retained VEGF 
responsiveness
In vitro angiogenesis; RT-qPCR, KDR, vWF, INSIG
Growth factor secretion
 Human
  Gramlich et al. [18] Human Small changes in growth factor secretion 
between fresh and cryopreserved cells
Human antibody-mediated growth factor array
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by Baust et al. [76] who stated, “unstudied but of con-
cern is the potential for the preservation process to 
select for increased resistance to preservation stresses”.
From Table 5, it can be concluded that there is a strong 
agreement that cryopreservation does not affect BM-
MSCs differentiation potential. This conclusion is of 
value to fulfil one of the 2006 ISCT criteria for MSCs. 
However, differentiation potential may become less 
important for cell therapy. For example, in heart disease, 
MSCs’ initial mechanism of regeneration was outlined 
as differentiation into cardiomyocytes and incorpora-
tion into the host tissue. Recently, this outline has been 
updated to shed a light on a more effective regeneration 
mechanism and that is their associated paracrine signal-
ling [75]. In fact, paracrine signalling is not confined to 
cardiac regeneration but is now generally considered as 
the MSCs main mode of action. Caplan [77] suggested 
that it is “time to change the name” of MSCs to “Medici-
nal Signalling Cells” in order to better describe the secre-
tion of trophic factors. According to Gonzalez et al. [78] 
“80% of the therapeutic effect of stem cells is attributed to 
paracrine actions”.
The  MSCs secretome is composed of growth factors 
and cytokines either soluble or engulfed in exosomes 
and/or vesicles [75, 79, 80]. MSC paracrine signalling is 
described as exerting plethora of effects including induc-
tion of angiogenesis, regulation of immune response 
and inflammation, modulation of cell differentiation 
and proliferation, extracellular matrix formation, neu-
roprotective and neurotrophic effects, anti-apoptotic, 
anti-tumour and anti-microbial activities [81, 82]. Yet 
despite such a compelling list of activities no comprehen-
sive evaluation of the MSC secretome, and or its cell-free 
utility, has been conducted [83]. Data on the BM-MSCs 
secretome upon thawing is very limited and so is the 
data on angiogenic potential. There are only two studies 
which concluded that no effect of cryopreservation was 
observed (Table 9).
At an injury site, MSC contribute to the creation of an 
anti-inflammatory environment by suppressing the acti-
vation and proliferation of pro-inflammatory cells and 
promoting anti-inflammatory cells [84]. This modulation 
of both the innate and adaptive immune system can be 
accomplished in two ways: via cell–cell interaction and 
cell–cell communication through an array of soluble fac-
tors including indoleamine 2,3-dioxygenase (IDO) and/
or extracellular vesicles [85]. These characteristics were 
the main contributors in raising the MSC profile as thera-
peutically valuable. As discussed above, MSC immune 
function has now become an essential indicator on MSC 
function. In view of this, it is expected that more stud-
ies on MSC immunomodulatory properties, and assays 
to evaluate them will emerge. Recently, Chinnadurai et al. 
[86] tested BM-MSCs potency using a matrix approach 
and concluded that cryopreservation negatively affects 
cells’ secretome with T cell proliferation. According to 
Table 9, eight studies assessed BM-MSCs immune func-
tion post-thaw with a balance of four concluding damag-
ing effect and four concluding no effect.
Conclusion
This systematic review has highlighted areas of agree-
ment and deviation that currently exist around BM-
MSCs properties and functions after cryopreservation 
(Fig. 4).
With MSC-based therapies expected to offer treatment 
choices for several conditions and diseases that are currently 
incurable and presently no MSC drug yet approved by the 
FDA the biological community must work towards repro-
ducible and reliable data sets to achieve regulatory accepted 
Fig. 4 Effects of cryopreservation on BM-MSC in terms of cellular 
attributes and function. From the systematic analysis performed, 
cryopreservation appears to influence viability and apoptosis, cellular 
attachment, immunomodulation and metabolism (cell schematics 
shown in blue on right-hand side). Whereas, no common significant 
effects mediated by cryopreservation have been documented in 
proliferation, morphology, differentiation or immunophenotyping 
(cell schematics given in green, red, orange and black on the 
left-hand side)
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drug status. With cryopreservation effects being fully identi-
fied and assessed in terms of therapeutic evaluation.
Continuing variance in our scientific approaches 
facilitates unapproved therapies and stem cell tourism 
[87, 88]; leading both the FDA and ISCT to urge both 
caution for individuals and request enhanced rigor, 
reproducibility and visibility from the scientific com-
munity [59, 89, 90]. “Successful new therapies come at a 
considerable cost that cannot easily be sustained with-
out evaluation and guidance” [89].
This review has been limited to one tissue source 
and that is bone marrow, yet we know that MSCs can 
be isolated from almost all tissues especially adipose 
and umbilical cord [17]. Including more tissue sources 
was beyond the scope of this review yet it is important 
to document the impact of cryopreservation on those 
MSC sources also.
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